This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.

1. www.immuno-oncology-conference.com
Register online or fax your registration to +44 (0) 870 9090 712
or call +44 (0) 870 9090 711
A: Strategic Competitive Intelligence in the
Immuno-Oncology space
Workshop Leaders:
Timos Papagatsias, CEO, LucidQuest Ventures
08.30 - 12.30
B: Could the Microbiome boost cancer immunotherapy?
Workshop Leaders:
Shahram Lavasani, CEO, ImmuneBiotech
Ramin Massoumi, Principal Investigator, Lund University
13:30 - 17:00
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS | TUESDAY 25TH SEPTEMBER 2018, COPTHORNE TARA HOTEL, LONDON, UK
SMi Pharma
@SMiPharm
#immunooncologySMi
CHAIR FOR 2018:
• James Legg, Vice President R&D, Crescendo Biologics
KEY SPEAKERS INCLUDE:
• Andrew Exley, Medical Assessor, MHRA
• Harry Smith, Medical Scientist, Gilead Sciences
• Grace Macaulay, Global Safety Physician Patient Safety
Oncology, MedImmune
• David Giljohan, CEO, Exicure
• Kandeepan Ganeshalingam, Executive Director, Oncology
Therapeutic Area Head, European Clinical Development,
MSD
• Rochana Wickramasinghe, Director of Oncology Evaluation,
AstraZeneca
HIGHLIGHTS IN 2018:
• Learn about targeting immune checkpoints with
Humabody VH Therapeutics
• Discover the recent advances in providing durable disease
control with Keytruda as an anti-cancer therapy
• Discuss the tumour mutation burden and the potential of its
use as an indication of treatment choice
• Develop an understanding of unwanted immunogenicity
and functionality testing of immuno-oncology drugs
• Gain insight into new techniques, such as the emerging
applications of liquid biopsies, in Immuno-Oncology
WORKSHOPS: 25TH
CONFERENCE: 26TH-27TH
SEPT
2018COPTHORNE TARA HOTEL, LONDON, UK
SMi presents the inaugural Conference on…
Immuno-Oncology
Propagating thought-provoking discussions on
novel targeted cancer therapies
REGISTER BY 30TH APRIL AND SAVE £400
REGISTER BY 31ST MAY AND SAVE £300
REGISTER BY 29TH JUNE AND SAVE £200

2. Immuno-Oncology
Day One | Wednesday 26th September 2018 www.immuno-oncology-conference.com
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
James Legg, Vice President R&D, Crescendo Biologics
KEYTRUDA, IMMUNE CHECKPOINTS AND ONCOLYTIC VIRUSES
9.10 Keytruda: anticancer therapy across a wide range of
malignancies
• Recent advances in providing durable disease control
• Innovative combination strategies to improve upon
monotherapy activity and overcome resistance
• Importance of patient selection in cancer immunotherapy
Kandeepan Ganeshalingam, Executive Director, Therapeutic Area
Head Oncology, Merck Sharp & Dohme
9.50 Targeting immune checkpoints with Humabody VH Therapeutics
• Crescendo Biologics’ development of Humabody VH
products, small highly adaptable and flexible proteins which
can be developed into differentiated therapeutics
• A description of Crescendo’s approach to developing
differentiated Immuno oncology therapeutics with several
examples of molecules in our research pipleline
• Case studies include a BiParatopic PD-1 inhibitor which shows
efficacy in an anti-PD-1 insensitive in vivo model, a BiSpecific
molecule inhibiting both PD-1 and LAG3 for overcoming
resistance or insensitivity to PD-1 inhibition and a Targeted IO
approach in which T-cell co-stimulation is focused away from
the periphery and into the tumour microenvironment in order to
improve the narrow therapeutic index observed with standard
T-cell agonist antibodies
James Legg, Vice President R&D, Crescendo Biologics Ltd
10.30 Morning Coffee
11.00 Enhanced cancer vaccine effectiveness with NKTR-214, a CD122-
biased cytokine
• NKTR-214 biases signalling through the IL-2 receptor pathway
to generate profound effector T-cell responses while reducing
regulatory T-cell activity in tumours
• Combination dosing of NKTR-214 dramatically enhances activity
of several tumour vaccine modalities in mouse models
• The unique profile of T-cell activity generated by NKTR-214 may
enable the next generation of tumour vaccines
Jonathan Zalevsky, Senior Vice President Biology & Preclinical
Development, Nektar Therapeutics
BISPECIFICS, PK-PD MODELING AND IMMUNOGENICITY
11.40 The use of Bispecific Antibodies to modulate anti-tumour
immune responses
• Bispecific antibodies: an attractive alternative to cancer
treatments combinations
• F-star’s approach to create bispecific mAb²
• In vitro and in vivo efficacy of F-star bispecific antibodies
targeting oncology pathway
Session reserved for F-Star (speaker to be confirmed)
12.20 Networking Lunch
13.30 Application of PK-PD modeling and simulation in development of
T-Cell redirecting antibodies
• Platform Target-Biologic-Effector Engagement Model
• Evaluation of key parameters (e.g. Target/T-cell affinity, E:T
Ratio) on Cytolysis and T-cell Activation
• Evolution of the developed platform model to Multi-specific
Biologics
• Preclinical-to-Clinical Translation
Aman Singh, PK-PD Scientist, Janssen
14.10 Unwanted immunogenicity and functionality testing of immuno-
oncology drugs
• Tools for early unwanted immunogenicity assessment: in silico
and in vitro assays
• In vitro functional testing to accelerate immune oncology drug
design
• Optimal early lead selection
Sofie Pattijn, Chief Technology Officer, ImmunXperts
14.50 Afternoon Tea
CAR-T CELLS AND THE TUMOUR MUTATION BURDEN
15.20 T4 CAR T cell immunotherapy of patients with refractory head and
neck cancer
• A CAR has been engineered using a promiscuous ligand that
engages 8 distinct ErbB dimer species
• Phase 1 evaluation has been initiated in patients with head and
neck cancer, using intra-tumoural delivery and phased dose
escalation to mitigate risk
• Thirteen patients have been safely treated to date, at doses of
up to 1Bn cells, without DLTs and with an efficacy signal evident
Caroline Hull, Research Associate, Kings College London
16.00 The tumour mutation burden and using this as an indication of
treatment choice
• The effect of a higher number of somatic mutations on the
susceptibility to treatment
• Why a higher somatic mutation rate increases the chance of
response to IO treatments
• How the tumour mutation burden can be harnessed to optimise
the effect of therapies
• The cut off points used and the validation of this point
Harry Smith, Medical Scientist, Gilead
16.40 Chairman’s Closing Remarks and Close of Day One
Register online at www.immuno-oncology-conference.com
SUPPORTED BY
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime
networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your
industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

3. Immuno-Oncology
www.immuno-oncology-conference.com Day Two | Thursday 27th September 2018
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
James Legg, Vice President R&D, Crescendo Biologics
COMBINATION THERAPIES
9.10 Combining cancer vaccines with T cell co-stimulatory
receptor agonists
• T cell co-stimulatory receptor agonists have had a modest
impact within the context of Immuno-Oncology
• In vitro and in vivo examples of enhanced potency within the
context of antigen-specific T cell priming
• Future directions and opportunities for academic / biotech
collaborations
Scott Robbins, Principal Scientist, MedImmune
9.50 IO/ADC combination therapies
• Combining ADC and IO therapies
• ADC/IO Case Studies
• IO/PBD-ADC combinations
- Immunomodulatory properties
- Synergy with immunotherapies
Philip Howard, Chief Scientific Officer, Spirogen
10.30 Morning Coffee
11.00 Innate Immune Activators- Spherical Nucleic Acid TLR9 in
combination with checkpoint inhibitors
• Spherical Nucleic Acids (SNAs) are 3D forms of DNA and RNA
that enter cells naturally
• SNAs can be used to potently activate Toll-like-receptor (TLR)
pathways
• Pre-clincal work has shown activity in Breast, Lung, Melanoma,
and Colorectal cancers in combination with checkpoint
inhibitors
• Phase I normal volunteer studies were begun in October 2017,
results of which will be shared
David Giljohann, CEO, Exicure Inc.
REGULATIONS AND SAFETY CHALLENGES
11.40 Human tissue research in the UK: ethics and regulation
• Ethical approval and regulation of Human Tissue research
• The roles of the Health Research Authority (HRA)
• The roles of Human Tissue Authority (HTA)
Christopher Perrett, Regulation Manager, Human Tissue Authority
12.20 Networking Lunch
13.30 Generating symbiosis with regulatory affairs in
Immuno-Oncology
• How are the regulations keeping up with innovation and
evolving therapeutic approaches?
• The differentiation between European vs American procedures
of approval
• Is there likely to be a gap between patients’ therapeutic
access, restricted by approval procedures
• What are the current barriers to entry in the market?
Andrew Exley, Medical Assessor, MHRA
14.10 Key safety challenges in cancer immunotherapy clinical trials
• Immunotherapy past, present, and future
• Checkpoint inhibitors
• Key safety challenges: immune-mediated AEs
• ESMO/ASCO guidelines
• Way forward: getting the right balance
• Conclusion
Grace Macaulay, Global Safety Physician, Patient Safety-
Oncology, MedImmune
14.50 Afternoon Tea
CLINICAL COLLABORATIONS AND LIQUID BIOPSIES
15.20 Clinical collaborations in IO — why do them and what pharma
looks for
• History of clinical collaborations in IO
• How IO clinical collaborations have changed the business
model for how pharma and biotech interact
• Why should biotechs enter into an IO clinical collaboration with
pharma?
• What does pharma look for in a biotech when deciding
whether or not to enter into a clinical collaboration?
Rochana Wickramasinghe, Evaluation Director, AstraZeneca
16.00 Emerging applications of liquid biopsies in immuno-oncology
• An introduction to the field of liquid biopsies will be given, and
the biology explored
• Technologies and platforms for circulating tumour DNA (ctDNA)
analysis will be outlined and appraised
• Clinical applications of liquid biopsies in oncology will be
explored
• Recent data on the use of liquid biopsies for monitoring
immunotherapy will be discussed
Jonathan Wan, MD, PhD Student, Cancer Research UK
16.40 Chairman’s Closing Remarks and Close of Day Two
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
SUPPORTED BY
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Lyudmyla Durneva, SMi Marketing on +44 (0) 20 7827 6088 or
email: ldurneva@smi-online.co.uk

4. HALF DAY PRE-CONFERENCE WORKSHOP A
Tuesday 25th September 2018
Copthorne Tara Hotel, London, UK
8.30 - 12.30
Strategic Competitive Intelligence
in the Immuno-Oncology space
Workshop Leader:
Timos Papagatsias, CEO, LucidQuest Ventures
Workshop overview:
This workshop will focus on how stakeholders can combine the
latest advancements in Strategic Competitive Intelligence in
order to uncover opportunities and threats for their companies
and brands in the Immuno-Oncology space. Workshop
participants will also be provided with a short step-by-step guide
on how to use competitive intelligence to generate actionable
insights which will help them gain a competitive advantage
over others.
Key benefits of attending:
• Learn about Strategic Competitive Intelligence and how to
generate actionable insights
• Understand how to most effectively conduct CI in the
Immuno-Oncology space and remain competitive
Agenda
08.30 Registration and coffee
09.00 Opening remarks and introductions
9.10 Session 1: Introduction to strategic competitive
intelligence
• What CI is, what it is not and how to do it
• What you can and what you cannot do with CI
• Evolution of CI and its tools
• Importance of CI in the I/O space
9.50 Session 2: How to gain or maintain a competitive
advantage in the I/O space, whether you are a
newcomer or established player
• What can you learn from your competitors and
the marketplace using CI in the I/O space?
• Using CI to support combination study design,
gain early insights in trial results, identify new
combination approaches, validate new targets,
develop modified patient journeys etc.
• Minimizing uncertainty in a rapidly moving space
• How to improve on databases using targeted
primary competitive intelligence
• How to use social media and social networks to
better monitor competitor activity and identify
emerging threats and opportunities
10.30 Morning Coffee
11.00 Session 3: “Future-proofing” your efforts by
identifying early warning signals and opportunities
for your company in I/O
• Short step-by-step guide / case study
11.40 Q&A
12.30 Closing Remarks and end of workshop
About the Workshop Leader:
Timos has over 10 years’ experience working as a strategy and
intelligence consultant across the Pharma / Biotech and the
Life Sciences Investment industries. He has advised 18 out of
20 top Pharma and Biotechnology companies and has also
worked with a large number of medium and small size firms on
multiple topics (market entry and market access optimization,
patient centricity, digital healthcare and social media, clinical
product development and trial design, brand positioning,
portfolio analysis etc.) across therapy areas and geographies.
He is currently the CEO of LucidQuest, a boutique strategic
intelligence consultancy that focuses both on traditional
therapy areas (oncology, haematology, immunology, CV/
Met, CNS etc.) as well as on developing insights into patient
centricity, digital healthcare / IoE and personalized medicine
(gene and cell therapies).
ORGANISATION SYNOPSIS:
LucidQuest provides strategic intelligence
and evidence-based investment insights
for the Life Sciences and other industries.
We partner with leading Pharma, Biotech
and Healthcare companies and consultancy firms, providing
support across multiple therapy areas (respiratory, CV & Met,
onco / haem, CNS, vaccines, gene and cell therapy etc.)
and also in the rapidly evolving Digital Healthcare / IoE space.
We further provide investment insights to hedge funds, PE, VC,
angel investors etc., leveraging our in-house and our network’s
scientific and commercial expertise.

5. HALF DAY PRE-CONFERENCE WORKSHOP B
Tuesday 25th September 2018
Copthorne Tara Hotel, London, UK
13.30 - 17.00
Could the Microbiome boost
cancer immunotherapy?
Workshop Leaders:
Shahram Lavasani, CEO, ImmuneBiotech
Ramin Massoumi, Principal Investigator, Lund University
Workshop overview:
The commensal microbiome is a key modulator of
host physiology and risk of diseases, including cancer
development and progression. Recent reports suggest
that the microbiome can modulate the efficacy of
anti-cancer treatment. This workshop will cover recent
advances in understanding of the complex role of
microbiome in health and disease and how microbes and
the microbiota may contribute to cancer development,
and responsiveness to cancer therapeutics. We will further
discuss the advantages and challenges of developing
microbiome based treatments.
Gain insights into:
• Understanding of the dynamics and function of the
human microbiome in health and disease
• Cancer and human microbiota
• Dysbiosis and Cancer Therapy
• Immunostimulation by the microbiome
• Microbial interventions
Agenda
13.30 Registration and coffee
14.00 Opening remarks and introductions
14.10 Session 1: The role of human microbiome in
health and disease
• Microbiome, a young and challenging field
• Dysbiosis, cause or consequence?
• Microbial education of the immune system
14.50 Session 2: Microbiome in cancer
development and therapy
• Dysbiosis and cancer
• The gut microbiome and immuno-oncology
• The impact on the action of Immune
checkpoint Inhibitors
• Microbiota targeted therapies and impact
on oncological treatment efficacy
• The benefits of the Probiotics
15:20 Morning Coffee
15.50 Session 3: What is the next step
• General discussions on the advantages and
challenges in development of microbiome
based therapies
16.30 Q&A
17.00 Closing Remarks and end of workshop
About the Workshop Leader:
Shahram Lavasani holds a PhD degree from Lund University
in Medical Inflammation Research where he studied
the immunoregulation and novel immunotherapies in
multiple sclerosis (MS) followed by two years of post doc at
department of the surgery at University hospital in Malmö/
Sweden. He is a skillful immunologist, with many years
of teaching and research expertise on gastrointestinal
complications in autoimmune and chronic inflammatory
diseases. Focusing on Gut-Brain axis he has pioneered
research in MS, which is an autoimmune disease of the
central nervous system, by demonstrating inflammation
and increased permeability in the gut and introduced
microbiota-basedtherapiesusingcombinationofprobiotic
bacteria. He is the founder of ImmuneBiotech, developed
a proprietary lactobacilli library and established accurate
and multiple selection technologies to screen and design
formulations for the optimal therapeutic management of
the diseases.
About the Organisation:
ImmuneBiotech discovers and develops
novel bacterial-based therapeutics
targeting the gut microbiota and the
immune system. The company has
access to an exclusive bacterial library,
established an advanced screening
platform and developed a unique
know-how to develop bacterial solutions
to modulate the microbiome also with
impact on the gut barrier function and
the immune system. The company´s GutMagnific™ has
shown great success in treatment of IBS and will soon be
launched on the market.

6. IMMUNO-ONCOLOGY
Conference: 26th -27th September 2018, Copthorne Tara Hotel, London, UK Workshops: 25th September 2018, Copthorne Tara Hotel, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
ONLINE at www.immuno-oncology-conference.com
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Unique Reference Number
Our Reference P-295
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-295 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here
CONFERENCE PRICES GROUP DISCOUNTS AVAILABLE
I would like to attend: (Please tick as appropriate) Fee TOTAL
□ Conference 2 Workshops £2697.00 + VAT £3236.40
□ Conference 1 Workshop □ A □ B £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops only £1198.00 + VAT £1437.60
□ 1 Workshop only □ A □ B £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject
to distribution rights by speakers. Please note that some presentations may not be
available for download. Access information for the document portal will be sent to
the e-mail address provided during registration. Details are sent within 24 hours post
conference.
□ Book by 30th April to receive £400 off the conference price
□ Book by by 31st May to receive £300 off the conference price
□ Book by 29th June to receive £200 off the conference price
EARLY BIRD
DISCOUNT
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about our
events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we
have to cancel the event for any reason, then we will make a full refund immediately, but disclaim
any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policy please go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://www.smi-online.co.uk/opt-out
Terms and Conditions of Booking
DELEGATE DETAILS
VENUE Copthorne Tara Hotel, London, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712